Clinical trials: Metastatic Liver Cancers
Metastatic Esophageal, Gastric Cancer
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
This is an investigator-initiated industry-supported phase 1 clinical trial conducted in the phase 1 clinic at The University of Texas MD Anderson Cancer Center who will hold the Investigational New Drug (IND).
- Conditions
- Metastatic Esophageal, Gastric Cancer, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT05075993
- Testing
- LVGN3616 + LVGN6051 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide, LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel
- Where
- United States
- Volunteers
- 352 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatic Cancer, Metastatic Cancer
Prevention and Treatment of Complications of Endovascular Methods in Patients With Malignant Liver Tumors
In the structure of malignant liver lesions, two main groups are distinguished - primary liver cancer and metastatic liver damage. The five-year survival rate of patients with malignant liver tumors does not exceed 6%.
- Conditions
- Hepatic Cancer, Metastatic Cancer, Chemotherapy Effect
- Trial name
- PATOC (NCT04764409)
- Testing
- Chemoembolization, Chemoinfusion
- Where
- Russia
- Volunteers
- 500 people
- Sponsor
- Central Clinical Hospital RZD-Medicine, Russian Federation
Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma
Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment
Patients suffering from advanced stage hepatocellular carcinoma (HCC) who have shown disease progression during lenvatinib-based first line treatment, will be enrolled in this trial.
- Trial name
- NCT04511455
- Testing
- Cabozantinib
- Where
- 10 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Gastrointestinal Tumors
Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)
This is an open, multi-cohort, multi-center, exploratory and phase II clinical trial. To evaluate the efficacy and safety Anlotinib combined with chemotherapy as first-line and maintenance therapy for Gastrointestinal Tumors with…
- Trial name
- ALTER-G-001 (NCT05262335)
- Testing
- Anlotinib + Oxaliplatin + Capecitabine, Anlotinib + Cisplatin + Paclitaxel/ Docetaxel, Anlotinib + Standard first-line chemotherapy
- Where
- 7 sites in China
- Volunteers
- 116 people
- Sponsor
- Ruijin Hospital
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc)
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment.
- Conditions
- Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms
- Trial name
- NCT05286814
- Testing
- Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Circulating Tumor Cell
Circulating Tumor Cell Capture for Early Diagnosis and Postoperative Tumor Recurrence Monitoring of Liver Cancer
Through the screening of CTCs in patients with suspected liver cancer and liver tumor resection or liver transplantation, the number of CTCs in the blood of liver cancer patients before and after surgery is monitored, and the…
- Trial name
- NCT04688606
- Testing
- Circulating tumor cell capture technology
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Zhongnan Hospital
Colorectal Cancer
A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer
The multicenter, open-label, single-arm, non-randomized, two-stage Simon's design, phase II study (The CLMO-001 Trial) will evaluate the efficacy and safety of bevacizumab in combination with mFOLFOX-6 (Levofolinic acid…
- Trial name
- NCT01383707
- Testing
- 5-Fluorouracil (5-FU), Bevacizumab, Levofolinic acid
- Where
- 11 sites in Italy
- Volunteers
- 77 people
- Sponsor
- Hoffmann-La Roche
Stomach Neoplasms
A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis
The goal of this clinical trial is to observe the efficacy and safety of Sintilimab (a PD-1 inhibitor) combined with Ramucirumab (a VEGFR-2 antagonist) and chemotherapy as a first-line treatment for patients with advanced gastric…
- Trial name
- NCT06564298
- Testing
- Sintilimab, Ramucirumab, SOX/XELOX
- Volunteers
- 39 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
This phase II trial investigates the effect of combining two immune therapies, atezolizumab and CDX-1127 (varlilumab), with or without cobimetinib, in treating patients with biliary tract cancer that cannot be removed by surgery…
- Conditions
- Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Recurrent Distal Bile Duct Adenocarcinoma
- Trial name
- NCT04941287
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 29 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer With Liver Metastasis
A Prospective Multicenter Study: Ivosimab + Chemotherapy as Neoadjuvant for Resectable pMMR/MSS CRC Liver Mets
The population receiving ivosimab combined with chemotherapy for neoadjuvant treatment of colorectal cancer liver metastasis.
- Trial name
- NCT06972498
- Testing
- Patients will receive ivosimab combined with the XELOX/FOLFOX regimen, followed by radical surgery 4-6 weeks after the last dose; adjuvant chemotherapy will continue for 3 months postoperatively.
- Volunteers
- 35 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Liver Ablation, Liver Cancer
A Retrospective Registry of Intelliblate DUAL Channel Microwave Ablation
This study reviews past patient records from multiple hospitals to learn how safe and effective the IntelliBlate Microwave Ablation System is when used to treat liver tumors with two probes at the same time.
- Conditions
- Liver Ablation, Liver Cancer, Liver Cancer (Primary and Metastatic)
- Trial name
- DUAL (NCT07900984)
- Testing
- Intelliblate Microwave Ablation (MWA) System
- Volunteers
- 63 people
- Sponsor
- Varian, a Siemens Healthineers Company
Colorectal Neoplasms
Safety and Efficacy of Targeted Gene Transfer in Colorectal Cancer Metastatic to Liver
This is a Phase I safety study of a gene transfer drug for colorectal cancer that has spread to the liver. The main purpose of this study is to determine if it is safe to give this new intervention to persons with cancer, but we…
- Trial name
- NCT00035919
- Testing
- Mx-dnG1 Retroviral Vector
- Sponsor
- University of Southern California
Metastatic Colorectal Cancer
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
To determine if sorafenib when added to chemotherapy will slow disease progression more than chemotherapy alone in patients previously untreated for metastatic colorectal cancer.
- Trial name
- NCT00865709
- Testing
- Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
- Where
- 116 sites in United States, Belgium and 8 more
- Volunteers
- 198 people
- Sponsor
- Bayer
Liver Cancer (Primary and Metastatic), Liver Ablation
Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic Malignancies
Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic Malignancies
- Trial name
- NCT07459309
- Testing
- Multimodal Tumor Thermal Ablation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fudan University
Liver Metastasis Colon Cancer
Gadoxetate Abbreviated MRI in Metastatic Colorectal Cancer
After a patient is diagnosed with colon cancer, they receive a CT of the chest, abdomen, and pelvis to see if the cancer has spread (metastasized) to other parts of the body.
- Trial name
- NCT05314400
- Testing
- Full Gadoxetate-enhanced liver MRI, Shortened Gadoxetate-enhanced liver MRI
- Where
- 2 sites in Canada
- Volunteers
- 200 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Gastrointestinal Carcinoma, Pancreatic Cancer
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
Background: Gastrointestinal (GI) cancer affects the organs (such as the stomach, large and small intestine, pancreas, colon, liver, and biliary system) of the digestive tract.
- Conditions
- Gastrointestinal Carcinoma, Pancreatic Cancer, Hepatocellular Cancer, Cholangiocarcinoma
- Trial name
- NCT06690281
- Testing
- KRAS TCR-Transduced PBL, Aldesleukin, Fludarabine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer, Metastatic Cancer
Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00093444
- Testing
- lyso-thermosensitive liposomal doxorubicin, radiofrequency ablation
- Where
- 2 sites in United States, China
- Volunteers
- 30 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Liver Cancer
Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, doxorubicin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00471484
- Testing
- recombinant interferon alfa-2b, doxorubicin hydrochloride, fluorouracil
- Where
- Singapore
- Volunteers
- 54 people
- Sponsor
- National Cancer Centre, Singapore
Cancer, Advanced Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population.
- Conditions
- Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
- Trial name
- NCT06440005
- Testing
- AGX101
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Angiex, Inc.
Pancreatic Neoplasms, Neoplasm Metastasis
Hepatic Resection for Metastatic Pancreatic Cancer
The purpose of this study is to demonstrate the feasibility of an aggressive multimodal approach among patients with stage IV pancreatic cancer (PAC) with isolated, low-volume hepatic metastasis (LVHM).
- Conditions
- Pancreatic Neoplasms, Neoplasm Metastasis, Liver Metastases
- Trial name
- NCT02892305
- Testing
- Hepatic Resection or Ablation with Pancreaticoduodenectomy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Duke University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.